Pulmonx to Present at the Citi 2022 Virtual Healthcare Conference
Pulmonx Corporation (Nasdaq: LUNG) announced its participation in the Citi 2022 Virtual Healthcare Conference on February 24, 2022, at 8:45 AM PT / 11:45 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pulmonx Corporation (Nasdaq: LUNG) announced its participation in the Citi 2022 Virtual Healthcare Conference on February 24, 2022, at 8:45 AM PT / 11:45 AM ET. The event will feature a fireside chat with the company's leaders discussing their innovative treatments for severe lung disease. A live and archived webcast will be available on the Investors section of Pulmonx's website. Pulmonx specializes in minimally invasive solutions, notably the Zephyr® Endobronchial Valve, which has been approved by the FDA and is available in over 25 countries, treating more than 25,000 patients.
Details
News Market Reaction – LUNG
The recorded move for LUNG in the trading session of this news was -1.53%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Citi 2022 Virtual Healthcare Conference on Thursday, February 24, 2022, at 8:45AM PT / 11:45AM ET.
A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.